The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
Guardado en:
Autores principales: | Osama A. Amin, Ahmed F. Alaarag |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
KARE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/75af4dbb90c54e219eeebabf7885a646 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
por: M Rizzo, et al.
Publicado: (2020) -
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Mauro Gori, et al.
Publicado: (2021) -
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang C, et al.
Publicado: (2021) -
Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
por: M Rizzo, et al.
Publicado: (2020) -
Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Marco Rossato, et al.
Publicado: (2020)